Bariatric surgery modulates plasma levels of antibodies against angiotensin II type 1 and endothelin 1 type A receptor in severe obesity.

What Was Tested

Researchers studied Angiotensin II and Endothelin-1 in this observational study publication.

The contribution of endothelial-targeted autoantibodies against the angiotensin II type 1 receptor (anti-AT1R) and the anti-endothelin 1 type A receptor (anti-ETAR1) has been proposed in the development of cardiovascular diseases.

However, no data have been reported yet in obesity.

In this observational study the researchers evaluated the relationship between anthropometric and metabolic parameters and anti-AT1R and anti-ETAR1 concentrations in a cohort of patients with severe obesity and associated comorbidities undergoing bariatric surgery.

Who Took Part

The abstract describes 36 subjects taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Clinical evaluation and metabolic assessment were performed in 36 subjects referring to their Center for the Study and Integrated Treatment of Obesity at the University Hospital of Padova.

Circulating inflammatory adipocytokines and the endothelial dysfunction marker asymmetric dimethylarginine (ADMA) were evaluated; plasma levels of anti-AT1R and anti-ETAR1 were also determined. 10 normal-weight subjects were considered as a control group. 29 patients out of 36 were re-evaluated after surgery.

What Was Measured

The subject headings attached to it are Receptor, Angiotensin, Type 1, Obesity, Morbid, Autoantibodies, Bariatric Surgery, Receptor, Endothelin A and Biomarkers.

The authors tagged it with the keywords Angiotensin II receptors and Endothelin 1 receptors.

What This Means in Plain Language

This is an observational study of Angiotensin II and Endothelin-1 in 36 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Angiotensin II compound page and the Endothelin-1 compound page, all human trials.